KRAS+ NSCLC Fighters
493 views | +0 today
Follow
KRAS+ NSCLC Fighters
News and information for KRAS+ NSCLC Fighters
Curated by Kevin Fossett
Your new post is loading...
Your new post is loading...
Scooped by Kevin Fossett
Scoop.it!

Targeting Hsp90: Researchers Aim to Thwart Chaperones of the 'Guardian of the Proteome'

Targeting Hsp90: Researchers Aim to Thwart Chaperones of the 'Guardian of the Proteome' | KRAS+ NSCLC Fighters | Scoop.it
Hsp90 may be referred to as the 'guardian of the proteome,' since it regulates the correct structure and function of many of the important proteins encoded by our DNA.
more...
No comment yet.
Scooped by Kevin Fossett
Scoop.it!

Synta Rises on Potential for Novel Cancer Therapy

While the focus has been on people with mutations in the ALK gene, patients with mutations in the KRAS gene and those with high levels of lactate dehydrogenase may also benefit

more...
No comment yet.
Scooped by Kevin Fossett
Scoop.it!

ArQule ready for Phase 3 lung cancer trial

ArQule ready for Phase 3 lung cancer trial | KRAS+ NSCLC Fighters | Scoop.it
ArQule Inc. (Nasdaq: ARQL) of Woburn and its partner, Tokyo-base Daiichi Sankyo Co. Ltd., have completed enrollment for a Phase 3 trial of ArQule’s lead drug candidate to treat patients with locally-advanced or metastatic, non-squamous, non-small cell lung cancer (NLCLC).
more...
No comment yet.
Scooped by Kevin Fossett
Scoop.it!

Selumetinib plus docetaxel versus DOC for advanced KRAS

Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC) (Abstract #7503) ...
more...
No comment yet.
Scooped by Kevin Fossett
Scoop.it!

Array BioPharma Announces Clinical Data Presentations at the 2012 ASCO Annual Meeting

Array BioPharma Announces Clinical Data Presentations at the 2012 ASCO Annual Meeting | KRAS+ NSCLC Fighters | Scoop.it

... randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung ...

more...
No comment yet.
Scooped by Kevin Fossett
Scoop.it!

KRAS-Mutant Lung Cancers Are Addicted to GATA2

Researchers are exploring a new treatment for KRAS based on a KRAS dependency on another gene called GATA2, using a pair of drugs that already exist - Velcade (bortezomib) + Fasudil.

more...
No comment yet.
Scooped by Kevin Fossett
Scoop.it!

Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2012

Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2012 | KRAS+ NSCLC Fighters | Scoop.it

Array expects that further data and analyses will be presented in the second quarter of 2012 for the randomized Phase 2 trial conducted by AstraZeneca comparing selumetinib in combination with docetaxel versus docetaxel alone in the second-line treatment of patients prospectively selected with KRAS-mutant, locally advanced or metastatic, non-small cell lung cancer.

more...
No comment yet.
Scooped by Kevin Fossett
Scoop.it!

KRAS Mutation May Affect PFS in Lung Cancer

Mutant KRAS status in non-small cell lung cancer (NSCLC) correlated with significantly worse progression-free survival (PFS) and resistance to platinum-based chemotherapy, data from a randomized trial showed.

more...
No comment yet.
Scooped by Kevin Fossett
Scoop.it!

Synta - Exploring Galaxy And Beyond

Synta - Exploring Galaxy And Beyond | KRAS+ NSCLC Fighters | Scoop.it

Ganetespip has demonstrated clear evidence of clinical activity, including prolonged tumor shrinkage in patients, according to Synta. The most advanced trial with Ganetespip, dubbed GALAXY, is evaluating the compound's potential in the treatment of advanced non small cell lung cancer.

more...
No comment yet.
Scooped by Kevin Fossett
Scoop.it!

Synta Pharmaceuticals FInancial Investment Report

Synta is developing Ganetespib, a potent, synthetic, small molecule inhibitor of Hsp90, a chaperone protein that is essential to the function of certain other proteins that drive the growth, proliferation, and survival of many different types of cancer.  This drug is being investigated for KRAS patients.

more...
No comment yet.
Scooped by Kevin Fossett
Scoop.it!

MET Receptor Pathway: A Bounty of Targeted Options Explored

MET Receptor Pathway: A Bounty of Targeted Options Explored | KRAS+ NSCLC Fighters | Scoop.it
The MET signaling network has emerged as an important target for cancer therapy, with a particularly significant role in controlling the cancer hallmarks of metastasis and angiogenesis.
more...
No comment yet.
Scooped by Kevin Fossett
Scoop.it!

Review of Ganetespib Results in Lung Cancer Presented at IASLC 12th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting

Results showed that ganetespib is active in non-small cell lung cancer; has a favorable safety profile as a monotherapy or in combination with docetaxel

more...
No comment yet.
Scooped by Kevin Fossett
Scoop.it!

Potential treatment target for KRAS-mutated colon cancer found

Researchers from the Massachusetts General Hospital (MGH) Cancer Center have identified a new potential strategy for treating colon tumors driven by mutations in the KRAS gene, which usually resist both conventional and targeted treatments.
more...
No comment yet.
Scooped by Kevin Fossett
Scoop.it!

Selumetinib Cracks Door to Targeted Therapy for KRAS-Mutant NSCLC : Internal Medicine News

CHICAGO – The oral investigational MEK inhibitor selumetinib has crossed a clinical hurdle in the treatment of KRAS-mutated non–small cell lung cancer, but it was not without a cost in terms of toxicity.
more...
No comment yet.
Scooped by Kevin Fossett
Scoop.it!

Study reports first success of targeted therapy in KRAS+ NSCLC

A novel compound has become the first targeted therapy to benefit patients with the most common genetic subtype of lung cancer. 

Participants in the study all had advanced stages of the disease. They received the standard chemotherapy agent docetaxel in combination with either selumetinib or a placebo.

more...
No comment yet.
Scooped by Kevin Fossett
Scoop.it!

ASCO 2012 abstract: Ganetespib (STA-9090) in combination with docetaxel versus docetaxel alone

 

Ganetespib administered at 200 mg/m2 weekly showed activity in pretreated patients with advanced NSCLC patients with ELM4-ALK translocation and KRAS mutations.

more...
No comment yet.
Scooped by Kevin Fossett
Scoop.it!

ASCO abstracts reveal added appeal for key cancer drug prospects - FierceBiotech

The avalanche of ASCO abstracts last night triggered a flurry of news reports about the most notable new data on experimental therapies to be revealed ahead of next month's big meeting in Chicago.
more...
No comment yet.
Scooped by Kevin Fossett
Scoop.it!

The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer

The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer | KRAS+ NSCLC Fighters | Scoop.it

► GATA2 is essential for RAS-pathway mutant non-small cell lung cancer (NSCLC) ► Gene expression and ChIP-seq studies reveal a GATA2 transcriptional network in NSCLC ► Gata2 loss suppresses tumor growth in autochthonous models of Kras mutant NSCLC ► Combined drug inhibition of GATA2-regulated pathways suppresses Kras mutant tumors

more...
No comment yet.
Scooped by Kevin Fossett
Scoop.it!

Existing drugs could treat smokers' lung cancer : Cancer Research UK

Existing drugs could treat smokers' lung cancer : Cancer Research UK | KRAS+ NSCLC Fighters | Scoop.it
A common cancer drug and a drug used for a rare condition affecting the heart could together treat an aggressive form of lung cancer called non-small cell lung cancer (NSCLC), according to a study published in Cell today...
more...
No comment yet.
Scooped by Kevin Fossett
Scoop.it!

Reconstructing targetable pathways in lung cancer by integrating transcriptome, proteome and phosphoproteome.

we are establishing a druggable pathway that is active in the KRAS-Dep but not in the KRAS-Ind phenotype, and so defining new potential druggable targets for treating KRAS dependent lung cancer.

more...
No comment yet.
Scooped by Kevin Fossett
Scoop.it!

NSCLC drug regimen approved in 2006 does not improve survival for older patients

Medicare insured patients age 65 years and older who received a regimen of bevacizumab added to the standard chemotherapy regimen carboplatin and paclitaxel did not have improved survival compared to patients who received the standard treatment of carboplatin and paclitaxel alone, according to a study in the April 18 issue of JAMA, a theme issue on comparative effectiveness research.

Analysis of a drug regimen approved by the F.D.A.
more...
No comment yet.
Scooped by Kevin Fossett
Scoop.it!

Not All KRAS Mutations Are Alike in Non–Small Cell Lung Cancer - The ASCO Post

Not All KRAS Mutations Are Alike in Non–Small Cell Lung Cancer - The ASCO Post | KRAS+ NSCLC Fighters | Scoop.it

In non–small cell lung cancer (NSCLC), there is conflicting evidence on whether KRASmutations are predictive of poorer outcome.

more...
No comment yet.
Scooped by Kevin Fossett
Scoop.it!

KRAS Gene Mutation and Amplification Status Affects Sensitivity to Antifolate Therapy

• Patients with lung cancer and KRAS mutation responded well to antifolate therapy.
• Response linked to downregulation of KRAS expression.
• Downregulation may render cells more susceptible to chemotherapeutic drug.
more...
No comment yet.
Scooped by Kevin Fossett
Scoop.it!

Mice guide human drug trial : Nature News & Comment

Mice guide human drug trial : Nature News & Comment | KRAS+ NSCLC Fighters | Scoop.it
Parallel approach to cancer study provides genetic insights.  Adding an experimental drug called selumetinib to standard chemotherapy may help to shrink lung tumours in patients with mutations in a gene called KRAS. The parallel study in the mouse revealed, however, that the drug may fail in those who also carry a mutation in a tumour-suppressor gene called LKB1.
more...
No comment yet.
Scooped by Kevin Fossett
Scoop.it!

Selumetinib (AZD6244, enhances anti-tumour efficacy when combined with conventional chemotherapy

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models

more...
No comment yet.